Healthcare entity

AMT-260

Product

All 1 tracked stories fall under one category: market-trends. Of the tracked stories, 1 of 1 also mention AMT-130, the most common co-covered peer. The tracked stories average 2 original sources each. AMT-260 appears in 1 tracked Healthcare story from March 3, 2026.

Last mentioned: Aug 5, 2026

RSS updates
Share

Entity pulse

Recent coverage · AMT-260

1 story
6 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about AMT-260

All 1 tracked stories fall under one category: market-trends. Of the tracked stories, 1 of 1 also mention AMT-130, the most common co-covered peer. The tracked stories average 2 original sources each. AMT-260 appears in 1 tracked Healthcare story from March 3, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 4 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering AMT-260. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Type B FDA Meeting Target

    Planned follow-up to define Phase III and regulatory path for AMT-130.

  2. AMT-260 Data Readout

    Expected clinical data from Phase I/IIa epilepsy study in H1 2026.

  3. Type A FDA Meeting

    Discussed AMT-130 approval pathway; alignment not yet reached.

  4. Fiscal Year End

    Closed 2025 with $622.5 million in liquidity.

Stories mentioning AMT-260 1

AMT-260 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.